In a previous cross‐sectional clinical study (Nabers et al, 2016a) that included neurochemical markers from cerebrospinal fluid (CSF) (such as Aβ(40), Aβ(42), Aβ(42/40), phospho‐tau, total‐tau), the sensor was applied to 141 patients with moderate‐to‐severe AD stages. The gene discussed is MAPT; the disease is Alzheimer disease.